The study compares the benefits of warm liver perfusion using the OrganOx metra device with the standard care of static cold storage and was carried out across seven European transplant centres. This is the world’s first multi-centre randomised clinical trial of its kind.
COPE transplanted its 220th liver, achieving their recruitment target, on 9 March 2016 at the Queen Elizabeth Hospital in Birmingham (UK) after being randomised to normothermic machine perfusion. In total, the trial recruited for 19 months with the first liver transplanted at the end of June 2014.
Margaux Laspeyres, COPE Project Manager, commented: ‘We are thrilled to have achieved this important milestone and would like to thank the entire WP2 team with particular thanks to all participating centres and OrganOx for their ongoing support. Congratulations to the entire team and we look forward to our trial's results.’
The team will now ensure a complete set of data follow-up for each trial patient before starting data analysis.
Read more about COPE’s liver trial.